此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

旨在评估JadiCell™(一种研究性脐带来源间充质干细胞疗法)在被诊断为急性呼吸窘迫综合征(ARDS)患者中的安全性及潜在治疗活性。

2026年9月28日 更新者:Breathe Biologics, Inc.

JadiCell™(脐带来源间充质干细胞)治疗急性呼吸窘迫综合征(ARDS)的III期临床研究

This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.

研究概览

详细说明

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammatory lung injury, impaired oxygen exchange, and high mortality. Current treatments are primarily supportive and include mechanical ventilation and intensive care management.

JadiCell™ is an investigational cellular therapy derived from human umbilical cord tissue. These cells possess immunomodulatory and regenerative properties and may reduce inflammatory lung injury through paracrine signaling, immune regulation, and tissue repair mechanisms.

Following intravenous administration, mesenchymal stem cells are known to localize within the pulmonary microvasculature where they interact with immune cells and injured lung tissue.

This study will evaluate the safety and potential clinical effects of intravenous JadiCell administration in patients with ARDS.

研究类型

介入性

注册 (估计的)

128

阶段

  • 第三阶段

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients currently hospitalized
  2. Laboratory confirmation of ARDS
  3. Aged between 18 and 80 years
  4. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
  5. SpO2 <94% on room air requiring supplemental oxygen above baseline
  6. PaO2/FiO2 <300 mmHg
  7. Bilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan
  8. Requiring one of the following ï High Flow Oxygen Therapy ï Non-invasive Positive Pressure Ventilation (NIPPV, e.g. BiPAP and CPAP) ï Invasive Mechanical Ventilation (INV = intubated)

Exclusion Criteria:

  1. Greater than 96 h since hospitalization at the time of enrollment
  2. Greater than 48 h since intubation at the time of enrollment
  3. A previous MSC infusion not related to this trial
  4. History of Pulmonary Hypertension (WHO Class III/IV)
  5. History of left atrial hypertension or decompensated left heart failure.
  6. Pregnant or lactating patient
  7. Unstable arrhythmia
  8. Patients currently receiving immunosuppression with exception of up to 10 mg Prednisone equivalents daily
  9. Patients currently receiving chronic dialysis
  10. Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO)
  11. Presence of any active malignancy (except non-melanoma skin cancer)
  12. Moderate to severe liver disease (AST and ALT >5 X ULN)
  13. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen at rest
  14. Septic Shock (with >1 vasopressor)
  15. Multi-organ failure
  16. Not expected to survive > 48 hours

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment

Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC.

Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC.

安慰剂比较:Control

Controls will receive two infusions of vehicle solution.

Subjects in the control group will be treated with two IV infusions of vehicle solution.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of Participants Alive and Free of Respiratory Failure
大体时间:60 days

The proportion of participants who are alive and free of respiratory failure following treatment with UC-MSC therapy.

60 days

次要结果测量

结果测量
措施说明
大体时间
1. All-Cause Mortality
大体时间:60 Days

Number of Participants Who Died (All-Cause Mortality)

60 Days
2. Survival Status
大体时间:31 Days

Number of Participants Alive at Day 31

31 Days
3. Incidence of Serious Adverse Events (SAEs)
大体时间:31 Days

Number of Participants Experiencing Serious Adverse Events (SAEs)

31 Days
4. Serious Adverse Event-Free Survival
大体时间:31 Days

Number of Participants Alive Without Serious Adverse Events

31 Days
5. Time to Clinical Recovery
大体时间:Up to 60 Days

Time to Clinical Recovery (Days)

Up to 60 Days
6. Time to Oxygen Requirement ≤ 40%
大体时间:Up to 60 Days

Time to Oxygen Requirement ≤ 40% (Days)

Up to 60 Days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年3月1日

初级完成 (估计的)

2027年10月31日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2026年3月10日

首先提交符合 QC 标准的

2026年3月13日

首次发布 (实际的)

2026年3月18日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅